Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Grifols SA ADR

GRF
Current price
9.81 EUR +0.52 EUR (+5.60%)
Last closed 8.41 USD
ISIN US3984384087
Sector Healthcare
Industry Drug Manufacturers - General
Exchange Madrid Exchange
Capitalization 6 579 044 864 USD
Yield for 12 month -5.05 %
1Y
3Y
5Y
10Y
15Y
GRF
21.11.2021 - 28.11.2021

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain. Address: Avinguda de la Generalitat, 152, Barcelona, Spain, 08174

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

10.69 USD

P/E ratio

31.4444

Dividend Yield

Current Year

+7 277 358 636 USD

Last Year

+6 694 450 332 USD

Current Quarter

+2 006 918 593 USD

Last Quarter

+1 794 732 949 USD

Current Year

+2 564 197 081 USD

Last Year

+2 463 546 842 USD

Current Quarter

+685 319 379 USD

Last Quarter

+715 823 232 USD

Key Figures GRF

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 1 111 435 008 USD
Operating Margin TTM 16.19 %
PE Ratio 31.4444
Return On Assets TTM 2.47 %
PEG Ratio 0.2152
Return On Equity TTM 2.82 %
Wall Street Target Price 10.69 USD
Revenue TTM 6 810 643 968 USD
Book Value 8.23 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 9.3 %
Dividend Yield
Gross Profit TTM 2 231 530 000 USD
Earnings per share 0.27 USD
Diluted Eps TTM 0.27 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY -66.7 %
Profit Margin 2.43 %

Dividend Analytics GRF

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

65 %

Dividend History GRF

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date 03.06.2021
Forward Annual Dividend Yield
Last Split Factor 2:1
Payout Ratio
Last Split Date 04.01.2016
Dividend Date 14.06.2021

Stock Valuation GRF

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 31.4444
Forward PE 11.8765
Enterprise Value Revenue 2.1026
Price Sales TTM 0.966
Enterprise Value EBITDA 10.384
Price Book MRQ 0.9312

Financials GRF

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators GRF

For 52 weeks

5.3 USD 12.15 USD
50 Day MA 7.83 USD
Shares Short Prior Month 7 567 503
200 Day MA 7.88 USD
Short Ratio 4.22
Shares Short 6 110 747
Short Percent 0.4 %

Dynamics of changes in the value of assets

B

B3K

181.70 EUR Ackermans & Van Haaren NV 0 (0%)
Detailed analytics
B

BOKF

100.80 USD BOK Financial Corporation -0.82 (-0.81%)
Detailed analytics
C

COLR

44.56 EUR Etablissementen Franz Colruyt NV -1.83 (-3.59%)
Detailed analytics
G

GDUB

2.84 EUR GERDAU S.A. PFD 0 (0%)
Detailed analytics
L

LUN

11.63 CAD Lundin Mining Corporation +0.05 (+0.61%)
Detailed analytics